MajorVitamin K antagonist anticoagulants×Vitamin K1, haemostatic, antidote for coumarin anticoagulant overdose
Updated · Methodology
Mechanism
Acenocoumarol inhibits the hepatic gamma-carboxylation of vitamin K-dependent clotting factors (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Vitamin K1 (phytomenadione) is needed to make factors II, VII, IX and X, and the phytomenadione SmPC explicitly names it as an antagonist of coumarin derivatives, including acenocoumarol (phytomenadione SmPC, AEMPS). Vitamin K1 is therefore the antidote to acenocoumarol. It can reverse the effect of acenocoumarol on clotting factors within 3–5 hours (acenocoumarol SmPC, AEMPS). Vitamin K1 starts to act 1–3 hours after an intravenous dose and 4–6 hours after an oral dose (phytomenadione SmPC, AEMPS). The same mechanism can make it harder to restore anticoagulation later. Vitamin K1 doses above 5 mg can cause resistance to further anticoagulant treatment for several days (generic acenocoumarol SmPC, AEMPS). After an intramuscular injection, the muscle keeps releasing vitamin K1 gradually, like a depot (phytomenadione SmPC, AEMPS). Foods rich in vitamin K, such as spinach, cauliflower and cabbage, can also weaken the effect of acenocoumarol (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is loss of the anticoagulant effect of acenocoumarol. The US vitamin K1 label warns that after correction of excessive anticoagulation, a patient who still needs anticoagulant therapy again faces the clotting hazards that existed before. An excessive vitamin K1 dose can also restore the conditions that allowed thromboembolism (vitamin K1 prescribing information, US Food and Drug Administration, FDA). Intramuscular injections in patients on anticoagulant treatment carry a risk of haematomas (phytomenadione summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After intravenous use, anaphylactoid reactions and vein irritation or phlebitis are very rare (phytomenadione SmPC, AEMPS). The US label reports severe and fatal hypersensitivity reactions, including anaphylaxis, with intravenous and intramuscular use (FDA).
Management
Phytomenadione 10 mg/mL must not be given intramuscularly to patients on anticoagulant treatment. In muscle it acts as a depot, makes it harder to return to anticoagulation and carries a risk of haematomas (phytomenadione summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Avoid intramuscular injections throughout acenocoumarol treatment (acenocoumarol SmPC, AEMPS). Choose the antidote dose of vitamin K1 according to the international normalised ratio (INR) and bleeding. According to the acenocoumarol SmPC, with an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS). For acenocoumarol, the phytomenadione SmPC gives 1–2 mg by mouth or intravenously at an INR of 5–8 without symptoms or with mild bleeding. At an INR above 8, it gives 3–5 mg by mouth or 1–2 mg intravenously. In severe bleeding, it gives 5 mg intravenously together with fresh frozen plasma, prothrombin complex concentrate or prothrombin and factor VII concentrates (phytomenadione SmPC, AEMPS). Older patients are more sensitive to reversal with vitamin K1, so give them doses at the lower end of the ranges. In severe liver disease, monitor the INR carefully after vitamin K1 (phytomenadione SmPC, AEMPS). The US label asks for the lowest possible vitamin K1 dose and regular INR checks (vitamin K1 prescribing information, US Food and Drug Administration, FDA). If anticoagulation is needed after vitamin K1 doses above 5 mg, heparin can be used temporarily, with acenocoumarol restarted at the same time. Stop heparin once the INR is in the therapeutic range (generic acenocoumarol SmPC, AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range. Whenever any drug is added or stopped, use close and frequent coagulation checks, for example twice a week (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fitomenadiona (nº registro 27262), sección 4.5 (2023)– AEMPS, CIMA, nº registro 27262, revisión 10/2023, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Fitomenadiona, Konakion 10 mg/ml (nº registro 27262), sección 4.3 (2023)– AEMPS, CIMA, nº registro 27262 (Konakion 10 mg/ml solución oral/solución inyectable, Cheplapharm; ficha común con Konakion 2 mg/0,2 ml pediátrico, nº 21610), revisión 10/2023 (texto revisado 12/2015), secciones 4.2, 4.3, 4.4, 4.8, 5.1 y 5.2
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.9 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.9
- FDA: Vitamin K1 (phytonadione) injectable emulsion (Hospira) prescribing information (2026)– FDA, DailyMed setid e8808230-2c44-44c6-8cab-8f29b6b34051 (Hospira), revisión 08/2026 (versión 23), Boxed Warning, secciones 2.1, 5.1 y 7